The IgE humoral response in OKT3-treated patients: Incidence and fine specificity

Transplantation

Volumn 61, Issue 4, 1996, Pages 577-581

  Abramowicz, Daniel ^a   Crusiaux, Alain ^a   Niaudet, Patrick ^b   Kreis, Henri ^b   Chatenoud, Lucienne ^b   Goldman, Michel ^a  

^a ERASME HOSPITAL   (Belgium)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOGLOBULIN E; OKT 3; STEROID;

ARTICLE; GRAFT REJECTION; HUMAN; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES; ANTIBODIES, ANTI-IDIOTYPIC; BINDING, COMPETITIVE; EPITOPES; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KINETICS; MICE; MUROMONAB-CD3;

EID: 0029958823     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199602270-00011     Document Type: Article

References (38)

1. Kung P, Goldstein G, Reinherz E, Schlossman S. Monoclonal antibodies defining distinctive human T cell surface antigens. Science 1979; 206: 347.
2. Acuto O, Reinherz EL. The human T-cell receptor: structure and function. N Engl J Med 1985; 312: 1100.
3. Kreis H, Legendre C, Chatenoud L. OKT3 in organ transplantation. Transplant Rev 1991; 5: 181.
4. DeMattos A, Norman DJ. OKT3 for treatment of rejection in renal transplantation. Clin Transplant 1993; 7: 374.
5. Abramowicz D, Norman D, Vereerstraeten P, et al. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survival. Kidney Int (in press).
6. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin 2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
7. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma. N Engl J Med 1989; 320: 1420.
8. Chatenoud L, Bach JF. Therapeutic monoclonal antibodies in transplantation. Transplant Proc 1993; 25: 473.
9. Chatenoud L. Immunologic monitoring during OKT3 therapy. Clin Transplant 1993; 7: 422.
10. Abramowicz D, Crusiaux A, Goldman M. Anaphylactic shock after retreatment with OKT3 monoclonal antibody [Letter]. N Engl J Med 1992; 327: 736.
11. Chatenoud L, Baudrihaye MF, Chkoff N, et al. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986; 137: 830.
12. Alegre ML, Collins AM, Pulito VL, et al. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J Immunol 1992; 148: 3461.
13. Abramowicz D, Goldman M, De Pauw L, et al. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation-a single-center, prospective, randomized study. Transplantation 1992; 54: 433.
14. Legendre C, Kreis H, Bach JF, Chatenoud L. Prediction of successful allograft rejection retreatment with OKT3. Transplantation 1992; 53: 87.
15. Goffin E, Lambert M, De Nayer P, et al. Spurious elevation of serum thyrothropin (TSH) after OKT3 administration. Nephrol Dial Transplant 1994; 9: 1500.
16. Del Prete G, Maggi E, Parronchi P, et al. IL-4 is an essential factor for the IgE synthesis induced in vitro by human T cell clones and their supernatants. J Immunol 1988; 140: 4193.
17. Vercelli D, Jabara H, Arai K, Geha R. Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens. J Exp Med 1989; 169: 1295.
18. Finkelman FD, Holmes J, Katona IM, et al. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990; 8: 303.
19. Punnonen J, Aversa G, Cocks BG, et al. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993; 90: 3730.
20. Defrance T, Carayon P, Billian G, et al. Interleukin 13 is a B cell stimulating factor. J Exp Med 1994; 179: 135.
21. Flamand V, Abramowicz D, Goldman M, et al. Anti-CD3 antibodies induce T cells from unprimed animals to secrete IL-4 both in vitro and in vivo. J Immunol 1990; 144: 2875.
22. Scott DE, Gause WC, Finkelman FD, Steinberg AD. Anti-CD3 antibody induces rapid expression of cytokine genes in vivo. J Immunol 1990; 145: 2183.
23. Yoshimoto T, Paul WE. CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994; 179: 1285.
24. Leo O, Van Mechelen M, Flamand V, et al. TH2 helper cells escape anti-CD3 mediated immunosuppression in vivo. J Am Soc Nephrol 1991; 2: 551.
25. Plaut M, Zimmerman EM. Allergy and mechanisms of hypersensitivity. In: Paul WE, ed. Fundamental immunology. New York: Raven Press, 1993: 1399.
26. Frenken LAM, Koene RAP, Tax WJM. The role of antibody isotype in IFN-g and IL-2 production during anti-CD3-induced T cell proliferation. Transplantation 1991; 51: 881.
27. Waid TH, Lucas BA, Thompson JS, et al. Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 1992; 53: 80.
28. Anasetti C, Martin PJ, Storb R, et al. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplantation 1992; 54: 844.
29. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23: 403.
30. Knight RJ, Kurrle R, McClain J, et al. Clinical evaluation of induction immunosuppression with a murine IgG2b monoclonal antibody (BMA 031) directed toward the human α/β-T cell receptor. Transplantation 1994; 57: 1581.
31. Parlevliet KJ, ten Berge IJ, Yong SL, et al. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J Clin Invest 1994; 93: 2519.
32. Alegre ML, Peterson LJ, Xu D, et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994; 57: 1537.
33. Schroeder TJ, First MR. Monoclonal antibodies in organ transplantation. Am J Kidney Dis 1994; 23: 138.
34. Soulillou JP. Relevant targets for therapy with monoclonal antibodies in allograft transplantation. Kidney Int 1994; 46: 540.
35. Turner MC, Holman JM. Late reactions during initial OKT3 treatment. Clin Transplantation 1993; 7: 1.
36. Norman DJ, Shield CF, Henell KR, et al. Effectiveness of a second course of OKT3 monoclonal anti-T cell antibody for treatment of renal allograft rejection. Transplantation 1988; 46: 523.
37. Bartosh SM, Aronson AJ, Swanson-Pewitt EE, Thistlethwaite JR. OKT3 induction in pediatric renal transplantation. Pediatr Nephrol 1993; 7: 45.
38. Werier J, Cheung AHS, Matas AJ. Anaphylactic hypersensitivity reaction after repeat OKT3 treatment. Lancet 1991; 337: 1351.